Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by need2stockupon Apr 18, 2012 8:11pm
338 Views
Post# 19810265

I know what the problem is

I know what the problem is

Pliaglis looks like snot. Need2.

THE FDA recently approved Pliaglis, a combination of two common topical anesthetics – ones that are applied to the skin. Pliaglis forms a gel-like mask that releases them.

THE FDA recently approved Pliaglis, a combination of two common topical anesthetics – ones that are applied to the skin. Pliaglis forms a gel-like mask that releases them.

Pliaglis video https://www.youtube.com/watch?v=6ECD_4bdWxg

Pliaglis sales were discontinueddue to manufacturing problems.The following information was provided by the manufacturer at www.pliaglis.com.

As of September 15, 2008 we will discontinue sale of Pliaglis® (lidocaine&tetracaine;) Cream 7%/7%. After this date we will be unable to fill any additional orders.

We took this action because of recurring inconsistent viscosity (thickness) of the product formulation. Our testing has found significant levels of variability in the viscosity parameter, resulting in a thicker cream which can make application of the product difficult.

While we continue to work diligently to address this challenge at every level, we feel it is in the best interest of all concerned to resolve this issue before we continue sales.

Bullboard Posts